Flagship Pioneering

Flagship Pioneering is a life sciences venture capital and innovation firm headquartered in Cambridge, Massachusetts. Founded in 1999 by Noubar Afeyan, the firm operates on an "institutional innovation" model, acting as a principal founder, funder, and operator rather than a traditional investor. Its core mission is to invent and build breakthrough platform companies that aim to transform human health and sustainability.

The firm specializes in creating "first-in-category bioplatform companies" across biotechnology, life sciences, health, and sustainability sectors. Flagship's unique approach involves systematically conceiving, creating, and resourcing new ventures from ideation through commercialization. Notable companies originated by Flagship include Moderna, known for its mRNA technology, as well as Indigo Agriculture, Inari Agriculture, Tessera Therapeutics, and Generate:Biomedicines.

As of July 2024, Flagship Pioneering manages $14 billion in assets and has founded over 100 companies with an aggregate value exceeding $70 billion. Recent developments include the launch of Serif Biomedicines in April 2026, focused on modified DNA as a new biotechnology, and the formation of Terion in June 2026, aimed at digital infrastructure for agriculture. The firm also announced a collaboration with AWS in April 2026 to accelerate drug discovery. Leadership includes Co-Founder and CEO Noubar Afeyan, with Adrian Rawcliffe appointed CEO-Partner and CEO of Etiome in January 2026.